2010 FDA Advisory Committee Recommendations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
You may also be interested in...
Amgen’s risk plans for Nplate
Amgen's biologic Nplate (romiplostim) will have a Risk Evaluation and Mitigation Strategy that will include a comprehensive patient educational program plus financial assistance for those who cannot afford the drug, according to an Amgen release prematurely issued July 14, which states that the drug had been approved. Amgen later reports that FDA will miss the July 23 user fee date for the product, submitted for treatment of thrombocytopenia in adults with chronic immune thrombocytopenic purpura. The user fee had been pushed back from April 23 after the firm submitted an extensive risk management plan. Nplate is widely expected to gain approval shortly; FDA's Oncologic Drugs Advisory Committee voted unanimously in favor of the biologic in March (1Pharmaceutical Approvals Monthly June 2008)
Dendreon To File Provenge BLA In 2006 Based On Survival Data
Dendreon plans to submit a BLA for its prostate cancer vaccine Provenge in 2006 following FDA feedback suggesting that existing data is sufficient for filing, the firm says.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011